Deaths from malaria have been driven down by 60% since 2000. But unchecked drug resistance could cause more than 100,000 new deaths each year. Vas Narasimhan, CEO of Novartis, explains how we could avert this tragedy with decisive action.
Survey results highlight the need for concerted action to guard against a fresh upsurge in the disease.
One man’s fascination with malaria helps fuel the search for new treatments
The disease hobbles families and economies.
The race is on to find a new treatment before resistance to today’s drugs becomes widespread.
The third Novartis Social Business stakeholder dialogue took place on November 21 in Basel.
Dr. Matchaba describes how his unique background can help guide the company’s access-to-medicine efforts.
Review the strategy and annual performance of Novartis and read letters from our Chairman and CEO.
This site is intended for a global audience.